Cardiol Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on the stock and has a $8.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Edward Nash has given his Buy rating due to a combination of factors surrounding Cardiol Therapeutics’ recent clinical trial results and future potential. The Phase II ARCHER trial, although not statistically significant in its primary endpoints, showed promising results with CardiolRx demonstrating a notable improvement in extracellular volume (ECV) and a significant reduction in left ventricular mass (LVM). This reduction in LVM is particularly encouraging as it suggests a positive impact on myocardial recovery, which could be beneficial for future trials and indications.
Furthermore, Nash notes that while the ARCHER trial results do not directly translate to the Phase III MAVERIC trial for recurrent pericarditis, the safety profile and positive LVM outcomes are promising indicators. The management’s focus on these results and the potential for a small, short-duration outcomes study in acute myocarditis also contribute to the optimistic outlook. Nash reiterates the Buy rating with a price target of $8, reflecting confidence in Cardiol Therapeutics’ strategic direction and clinical advancements.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.